| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 132 | 2025 | 969 | 14.300 |
Why?
|
| Female | 294 | 2025 | 12396 | 4.170 |
Why?
|
| Neoplasms | 42 | 2025 | 446 | 4.060 |
Why?
|
| Humans | 335 | 2025 | 17314 | 4.010 |
Why?
|
| Ovarian Neoplasms | 14 | 2022 | 52 | 3.670 |
Why?
|
| Diet | 58 | 2024 | 355 | 3.590 |
Why?
|
| Puberty | 21 | 2024 | 58 | 3.530 |
Why?
|
| Prospective Studies | 101 | 2025 | 1226 | 3.080 |
Why?
|
| Middle Aged | 184 | 2025 | 7836 | 2.990 |
Why?
|
| Obesity | 24 | 2020 | 814 | 2.980 |
Why?
|
| Aged | 165 | 2025 | 6084 | 2.930 |
Why?
|
| Body Mass Index | 36 | 2022 | 937 | 2.480 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2025 | 52 | 2.410 |
Why?
|
| Adult | 114 | 2025 | 7500 | 2.340 |
Why?
|
| Environmental Pollutants | 10 | 2019 | 53 | 2.140 |
Why?
|
| Social Support | 7 | 2024 | 207 | 2.060 |
Why?
|
| Risk Factors | 100 | 2025 | 3258 | 2.060 |
Why?
|
| Quality of Life | 12 | 2024 | 499 | 2.000 |
Why?
|
| Delivery of Health Care, Integrated | 6 | 2024 | 535 | 1.900 |
Why?
|
| California | 47 | 2025 | 2311 | 1.860 |
Why?
|
| Cardiovascular Diseases | 18 | 2025 | 532 | 1.760 |
Why?
|
| Environmental Exposure | 14 | 2019 | 121 | 1.680 |
Why?
|
| Chemotherapy, Adjuvant | 23 | 2025 | 75 | 1.540 |
Why?
|
| Child | 52 | 2025 | 2403 | 1.530 |
Why?
|
| Cohort Studies | 79 | 2025 | 2514 | 1.530 |
Why?
|
| Dietary Fats | 29 | 2019 | 89 | 1.520 |
Why?
|
| Neoplasm Staging | 27 | 2025 | 338 | 1.500 |
Why?
|
| Exercise | 20 | 2025 | 515 | 1.500 |
Why?
|
| Vitamin D | 7 | 2017 | 73 | 1.450 |
Why?
|
| Menarche | 9 | 2022 | 28 | 1.420 |
Why?
|
| Prognosis | 24 | 2023 | 603 | 1.290 |
Why?
|
| Cancer Survivors | 10 | 2025 | 101 | 1.280 |
Why?
|
| Life Style | 16 | 2023 | 316 | 1.270 |
Why?
|
| Proportional Hazards Models | 35 | 2025 | 701 | 1.270 |
Why?
|
| Biomarkers, Tumor | 12 | 2021 | 145 | 1.260 |
Why?
|
| Body Weight | 8 | 2025 | 203 | 1.260 |
Why?
|
| Vitamins | 10 | 2017 | 60 | 1.250 |
Why?
|
| Neoplasm Recurrence, Local | 14 | 2024 | 243 | 1.240 |
Why?
|
| Genetic Predisposition to Disease | 14 | 2025 | 372 | 1.240 |
Why?
|
| Ethnic Groups | 12 | 2018 | 451 | 1.190 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2019 | 33 | 1.170 |
Why?
|
| Lung Neoplasms | 14 | 2024 | 268 | 1.150 |
Why?
|
| Survivors | 9 | 2017 | 157 | 1.140 |
Why?
|
| Longitudinal Studies | 24 | 2025 | 674 | 1.130 |
Why?
|
| Surveys and Questionnaires | 45 | 2022 | 1282 | 1.130 |
Why?
|
| Medical Oncology | 5 | 2024 | 32 | 1.100 |
Why?
|
| Continental Population Groups | 9 | 2019 | 286 | 1.060 |
Why?
|
| Endometrial Neoplasms | 11 | 2008 | 37 | 1.060 |
Why?
|
| Young Adult | 32 | 2025 | 2465 | 1.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 12 | 2023 | 65 | 1.040 |
Why?
|
| Age Factors | 33 | 2019 | 878 | 1.010 |
Why?
|
| Adolescent | 44 | 2025 | 3538 | 1.010 |
Why?
|
| Health Services Research | 3 | 2017 | 202 | 1.010 |
Why?
|
| Feeding Behavior | 20 | 2021 | 163 | 1.010 |
Why?
|
| Aged, 80 and over | 33 | 2024 | 1925 | 1.000 |
Why?
|
| Neoplasms, Glandular and Epithelial | 2 | 2016 | 4 | 1.000 |
Why?
|
| Antioxidants | 10 | 2016 | 40 | 0.990 |
Why?
|
| Motor Activity | 8 | 2013 | 208 | 0.990 |
Why?
|
| Postmenopause | 36 | 2017 | 248 | 0.980 |
Why?
|
| Male | 76 | 2025 | 9804 | 0.960 |
Why?
|
| Halogenated Diphenyl Ethers | 3 | 2019 | 10 | 0.960 |
Why?
|
| Hydrocarbons, Chlorinated | 3 | 2019 | 6 | 0.960 |
Why?
|
| Medication Adherence | 6 | 2024 | 235 | 0.950 |
Why?
|
| Antineoplastic Agents | 7 | 2016 | 58 | 0.930 |
Why?
|
| Prenatal Exposure Delayed Effects | 3 | 2017 | 168 | 0.930 |
Why?
|
| Time-to-Treatment | 1 | 2024 | 18 | 0.880 |
Why?
|
| Diet Surveys | 15 | 2015 | 56 | 0.870 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2024 | 53 | 0.870 |
Why?
|
| Nutrition Assessment | 7 | 2017 | 26 | 0.870 |
Why?
|
| Follow-Up Studies | 33 | 2024 | 1151 | 0.860 |
Why?
|
| Receptors, Estrogen | 11 | 2025 | 53 | 0.840 |
Why?
|
| Dietary Supplements | 11 | 2016 | 85 | 0.830 |
Why?
|
| Coronary Disease | 14 | 2005 | 146 | 0.830 |
Why?
|
| Delivery of Health Care | 5 | 2022 | 390 | 0.820 |
Why?
|
| Hispanic Americans | 7 | 2021 | 375 | 0.810 |
Why?
|
| Mastectomy | 4 | 2024 | 35 | 0.810 |
Why?
|
| Energy Intake | 22 | 2015 | 98 | 0.800 |
Why?
|
| Electronic Health Records | 9 | 2025 | 704 | 0.800 |
Why?
|
| United States | 37 | 2025 | 3866 | 0.770 |
Why?
|
| Hypertension | 5 | 2025 | 469 | 0.760 |
Why?
|
| Diabetes, Gestational | 2 | 2016 | 311 | 0.730 |
Why?
|
| Genetic Testing | 4 | 2020 | 69 | 0.730 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2024 | 57 | 0.730 |
Why?
|
| Risk Assessment | 16 | 2020 | 1076 | 0.720 |
Why?
|
| European Continental Ancestry Group | 7 | 2021 | 476 | 0.720 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2016 | 52 | 0.710 |
Why?
|
| Vitamin E | 7 | 2011 | 20 | 0.700 |
Why?
|
| Terminal Care | 4 | 2025 | 45 | 0.680 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 2 | 0.680 |
Why?
|
| Adiposity | 3 | 2017 | 67 | 0.680 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2020 | 1 | 0.680 |
Why?
|
| Dietary Fiber | 10 | 2019 | 60 | 0.680 |
Why?
|
| Breast Feeding | 4 | 2019 | 113 | 0.670 |
Why?
|
| Paclitaxel | 4 | 2016 | 9 | 0.670 |
Why?
|
| Stress, Psychological | 2 | 2019 | 134 | 0.670 |
Why?
|
| Aromatase Inhibitors | 8 | 2023 | 33 | 0.660 |
Why?
|
| Cholesterol, HDL | 2 | 2020 | 69 | 0.660 |
Why?
|
| Metals | 2 | 2019 | 6 | 0.660 |
Why?
|
| African Americans | 6 | 2016 | 439 | 0.660 |
Why?
|
| Registries | 17 | 2020 | 460 | 0.650 |
Why?
|
| Family Characteristics | 2 | 2019 | 57 | 0.650 |
Why?
|
| Breast | 8 | 2017 | 84 | 0.650 |
Why?
|
| Socioeconomic Factors | 10 | 2020 | 605 | 0.630 |
Why?
|
| Insulin Resistance | 1 | 2020 | 128 | 0.630 |
Why?
|
| Alcohol Drinking | 14 | 2019 | 356 | 0.630 |
Why?
|
| Logistic Models | 17 | 2021 | 879 | 0.630 |
Why?
|
| Phenols | 6 | 2017 | 37 | 0.630 |
Why?
|
| Phthalic Acids | 6 | 2016 | 13 | 0.620 |
Why?
|
| Case-Control Studies | 23 | 2025 | 1098 | 0.600 |
Why?
|
| Cognition | 2 | 2024 | 81 | 0.600 |
Why?
|
| Polychlorinated Biphenyls | 3 | 2019 | 12 | 0.600 |
Why?
|
| Time Factors | 13 | 2020 | 1039 | 0.590 |
Why?
|
| Physician-Patient Relations | 3 | 2018 | 163 | 0.590 |
Why?
|
| Retrospective Studies | 19 | 2025 | 2415 | 0.580 |
Why?
|
| Health | 5 | 2015 | 32 | 0.570 |
Why?
|
| Edible Grain | 7 | 2001 | 14 | 0.570 |
Why?
|
| Receptors, Progesterone | 10 | 2018 | 50 | 0.560 |
Why?
|
| Incidence | 35 | 2025 | 1266 | 0.550 |
Why?
|
| Residence Characteristics | 8 | 2023 | 253 | 0.550 |
Why?
|
| American Cancer Society | 4 | 2020 | 12 | 0.550 |
Why?
|
| Taxoids | 2 | 2016 | 8 | 0.550 |
Why?
|
| Odds Ratio | 17 | 2020 | 640 | 0.550 |
Why?
|
| Organizational Objectives | 1 | 2017 | 14 | 0.540 |
Why?
|
| Education | 1 | 2017 | 14 | 0.540 |
Why?
|
| Vegetables | 14 | 2023 | 88 | 0.540 |
Why?
|
| Treatment Outcome | 18 | 2024 | 1160 | 0.540 |
Why?
|
| Employment | 2 | 2020 | 44 | 0.540 |
Why?
|
| Communication | 4 | 2023 | 178 | 0.530 |
Why?
|
| Linear Models | 9 | 2019 | 206 | 0.530 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2016 | 2 | 0.520 |
Why?
|
| Bridged-Ring Compounds | 1 | 2016 | 4 | 0.520 |
Why?
|
| Algorithms | 4 | 2023 | 223 | 0.520 |
Why?
|
| Breast Cancer Lymphedema | 1 | 2016 | 4 | 0.510 |
Why?
|
| Aging | 5 | 2015 | 160 | 0.510 |
Why?
|
| Iowa | 34 | 2005 | 38 | 0.500 |
Why?
|
| Heart Failure | 6 | 2025 | 401 | 0.500 |
Why?
|
| Survival Analysis | 12 | 2021 | 202 | 0.490 |
Why?
|
| Diet, Mediterranean | 2 | 2013 | 7 | 0.490 |
Why?
|
| Drug Dosage Calculations | 1 | 2015 | 2 | 0.480 |
Why?
|
| Pregnancy | 9 | 2022 | 1463 | 0.480 |
Why?
|
| Cisplatin | 1 | 2015 | 3 | 0.480 |
Why?
|
| Social Class | 7 | 2021 | 116 | 0.480 |
Why?
|
| CA-125 Antigen | 3 | 2020 | 6 | 0.470 |
Why?
|
| Complementary Therapies | 4 | 2016 | 41 | 0.470 |
Why?
|
| Ohio | 11 | 2019 | 23 | 0.470 |
Why?
|
| Fluorocarbons | 3 | 2023 | 14 | 0.470 |
Why?
|
| Infant Formula | 1 | 2015 | 9 | 0.460 |
Why?
|
| Early Detection of Cancer | 6 | 2023 | 529 | 0.460 |
Why?
|
| Puberty, Precocious | 3 | 2022 | 8 | 0.450 |
Why?
|
| Sexual Maturation | 4 | 2024 | 8 | 0.450 |
Why?
|
| Pesticides | 2 | 2015 | 8 | 0.450 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 5 | 0.440 |
Why?
|
| Flame Retardants | 2 | 2015 | 14 | 0.440 |
Why?
|
| Minerals | 1 | 2014 | 8 | 0.440 |
Why?
|
| Biomarkers | 12 | 2020 | 307 | 0.430 |
Why?
|
| Fruit | 10 | 2019 | 80 | 0.430 |
Why?
|
| Receptor, ErbB-2 | 8 | 2024 | 47 | 0.430 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2025 | 18 | 0.420 |
Why?
|
| Multivariate Analysis | 23 | 2016 | 535 | 0.420 |
Why?
|
| Osteoporosis | 4 | 2020 | 74 | 0.420 |
Why?
|
| Regression Analysis | 11 | 2025 | 270 | 0.420 |
Why?
|
| Endocrine Disruptors | 2 | 2015 | 9 | 0.420 |
Why?
|
| Colorectal Neoplasms | 6 | 2020 | 622 | 0.420 |
Why?
|
| Risk | 24 | 2020 | 496 | 0.420 |
Why?
|
| Diagnostic Imaging | 3 | 2019 | 42 | 0.410 |
Why?
|
| Calcium, Dietary | 5 | 2007 | 28 | 0.410 |
Why?
|
| Cognition Disorders | 1 | 2013 | 30 | 0.410 |
Why?
|
| Social Networking | 1 | 2013 | 19 | 0.400 |
Why?
|
| Food | 2 | 2012 | 36 | 0.400 |
Why?
|
| Research Design | 7 | 2024 | 336 | 0.400 |
Why?
|
| Health Promotion | 4 | 2020 | 279 | 0.390 |
Why?
|
| Educational Status | 8 | 2013 | 177 | 0.390 |
Why?
|
| Patient Compliance | 7 | 2020 | 277 | 0.390 |
Why?
|
| Metabolic Syndrome | 1 | 2012 | 65 | 0.370 |
Why?
|
| Women's Health | 8 | 2008 | 197 | 0.370 |
Why?
|
| Survival Rate | 10 | 2017 | 252 | 0.370 |
Why?
|
| Ascorbic Acid | 5 | 2011 | 18 | 0.370 |
Why?
|
| Trastuzumab | 4 | 2025 | 19 | 0.370 |
Why?
|
| Dyslipidemias | 1 | 2012 | 56 | 0.370 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2015 | 51 | 0.350 |
Why?
|
| Caregivers | 6 | 2023 | 128 | 0.350 |
Why?
|
| Dementia | 1 | 2013 | 121 | 0.350 |
Why?
|
| Nutritional Physiological Phenomena | 5 | 2006 | 14 | 0.350 |
Why?
|
| Health Behavior | 5 | 2019 | 346 | 0.350 |
Why?
|
| Pediatric Obesity | 2 | 2022 | 88 | 0.350 |
Why?
|
| Tamoxifen | 4 | 2023 | 55 | 0.340 |
Why?
|
| Lymphedema | 1 | 2010 | 8 | 0.340 |
Why?
|
| Body Constitution | 9 | 2001 | 39 | 0.340 |
Why?
|
| Environmental Monitoring | 4 | 2016 | 27 | 0.340 |
Why?
|
| Colonic Neoplasms | 9 | 2011 | 163 | 0.330 |
Why?
|
| Membrane Proteins | 2 | 2020 | 38 | 0.330 |
Why?
|
| Molecular Epidemiology | 5 | 2021 | 44 | 0.330 |
Why?
|
| Public Health Surveillance | 3 | 2019 | 43 | 0.320 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2012 | 664 | 0.320 |
Why?
|
| National Cancer Institute (U.S.) | 4 | 2017 | 16 | 0.320 |
Why?
|
| Mortality | 3 | 2000 | 116 | 0.320 |
Why?
|
| Smoking | 10 | 2022 | 429 | 0.320 |
Why?
|
| Epidemiologic Studies | 3 | 2014 | 29 | 0.310 |
Why?
|
| Mental Recall | 4 | 2017 | 29 | 0.310 |
Why?
|
| Disease Management | 3 | 2019 | 111 | 0.310 |
Why?
|
| Lignans | 3 | 2017 | 3 | 0.310 |
Why?
|
| Nutrition Surveys | 8 | 2015 | 56 | 0.310 |
Why?
|
| Diet, Vegetarian | 3 | 2021 | 13 | 0.300 |
Why?
|
| Adolescent Development | 1 | 2009 | 11 | 0.300 |
Why?
|
| Self Report | 5 | 2017 | 257 | 0.300 |
Why?
|
| Cotinine | 2 | 2019 | 7 | 0.300 |
Why?
|
| Overweight | 5 | 2017 | 266 | 0.300 |
Why?
|
| Age of Onset | 6 | 2016 | 70 | 0.300 |
Why?
|
| Nutritional Status | 5 | 2015 | 32 | 0.300 |
Why?
|
| Chi-Square Distribution | 4 | 2015 | 146 | 0.290 |
Why?
|
| Cross-Sectional Studies | 8 | 2024 | 1280 | 0.290 |
Why?
|
| Interviews as Topic | 6 | 2015 | 306 | 0.290 |
Why?
|
| New York City | 8 | 2016 | 24 | 0.290 |
Why?
|
| Comorbidity | 4 | 2025 | 560 | 0.290 |
Why?
|
| Vitamin A | 3 | 1996 | 14 | 0.280 |
Why?
|
| Meat | 9 | 2007 | 27 | 0.280 |
Why?
|
| San Francisco | 6 | 2023 | 59 | 0.280 |
Why?
|
| Epidemiologic Methods | 3 | 1999 | 72 | 0.280 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2025 | 9 | 0.280 |
Why?
|
| Asian Americans | 3 | 2019 | 163 | 0.270 |
Why?
|
| Cholesterol | 9 | 2007 | 82 | 0.270 |
Why?
|
| Isothiocyanates | 2 | 2024 | 8 | 0.270 |
Why?
|
| Folic Acid | 6 | 2010 | 29 | 0.270 |
Why?
|
| Emotions | 2 | 2021 | 34 | 0.260 |
Why?
|
| Health Status Disparities | 3 | 2019 | 149 | 0.260 |
Why?
|
| Physical Exertion | 1 | 2006 | 15 | 0.260 |
Why?
|
| Sensitivity and Specificity | 5 | 2020 | 298 | 0.260 |
Why?
|
| Nutrition Policy | 3 | 2015 | 19 | 0.250 |
Why?
|
| Phytoestrogens | 3 | 2013 | 7 | 0.250 |
Why?
|
| Combined Modality Therapy | 5 | 2020 | 114 | 0.250 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 271 | 0.250 |
Why?
|
| Nutritional Sciences | 2 | 1997 | 9 | 0.250 |
Why?
|
| Pilot Projects | 5 | 2020 | 211 | 0.250 |
Why?
|
| Fractures, Bone | 4 | 2020 | 92 | 0.250 |
Why?
|
| Primary Prevention | 1 | 2006 | 62 | 0.250 |
Why?
|
| Body Size | 4 | 2017 | 31 | 0.250 |
Why?
|
| Genome-Wide Association Study | 6 | 2025 | 248 | 0.250 |
Why?
|
| Dairy Products | 5 | 2007 | 23 | 0.240 |
Why?
|
| Environment | 1 | 2006 | 50 | 0.240 |
Why?
|
| Mammography | 6 | 2023 | 168 | 0.240 |
Why?
|
| African Continental Ancestry Group | 5 | 2021 | 144 | 0.240 |
Why?
|
| Flavonols | 2 | 2017 | 2 | 0.240 |
Why?
|
| Feasibility Studies | 4 | 2020 | 108 | 0.240 |
Why?
|
| Palliative Care | 2 | 2023 | 52 | 0.240 |
Why?
|
| Stroke | 4 | 2025 | 309 | 0.240 |
Why?
|
| Computational Biology | 2 | 2015 | 26 | 0.240 |
Why?
|
| Immunization, Secondary | 1 | 2025 | 59 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 3 | 2024 | 310 | 0.230 |
Why?
|
| Activities of Daily Living | 2 | 2024 | 81 | 0.230 |
Why?
|
| Population Surveillance | 7 | 2015 | 252 | 0.230 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2015 | 5 | 0.230 |
Why?
|
| Estrogen Replacement Therapy | 6 | 2008 | 100 | 0.230 |
Why?
|
| Quality of Health Care | 3 | 2018 | 259 | 0.220 |
Why?
|
| Neoadjuvant Therapy | 1 | 2024 | 13 | 0.220 |
Why?
|
| Brassicaceae | 2 | 2023 | 7 | 0.220 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2024 | 5 | 0.220 |
Why?
|
| Mitomycin | 1 | 2024 | 4 | 0.220 |
Why?
|
| Geriatric Assessment | 1 | 2024 | 43 | 0.220 |
Why?
|
| BCG Vaccine | 1 | 2024 | 8 | 0.220 |
Why?
|
| Patient Preference | 1 | 2025 | 49 | 0.220 |
Why?
|
| Neoplasm Invasiveness | 3 | 2024 | 79 | 0.220 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2025 | 363 | 0.220 |
Why?
|
| Health Maintenance Organizations | 3 | 2015 | 407 | 0.220 |
Why?
|
| Heart Arrest | 3 | 2025 | 33 | 0.220 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 2 | 0.220 |
Why?
|
| Lipoproteins | 3 | 1995 | 13 | 0.220 |
Why?
|
| Hormones | 1 | 2024 | 14 | 0.220 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2014 | 29 | 0.220 |
Why?
|
| Dietary Carbohydrates | 10 | 2003 | 28 | 0.210 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 66 | 0.210 |
Why?
|
| ras Proteins | 2 | 2014 | 20 | 0.210 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2014 | 32 | 0.210 |
Why?
|
| Reproducibility of Results | 9 | 2017 | 357 | 0.210 |
Why?
|
| Bone Density | 3 | 2020 | 94 | 0.210 |
Why?
|
| Models, Statistical | 3 | 2021 | 170 | 0.210 |
Why?
|
| Advance Care Planning | 1 | 2023 | 21 | 0.200 |
Why?
|
| Health Plan Implementation | 2 | 2020 | 35 | 0.200 |
Why?
|
| Qualitative Research | 2 | 2022 | 260 | 0.200 |
Why?
|
| Health Personnel | 3 | 2023 | 126 | 0.200 |
Why?
|
| RNA | 1 | 2022 | 12 | 0.200 |
Why?
|
| Menopause | 7 | 2000 | 68 | 0.200 |
Why?
|
| Fertility Preservation | 1 | 2022 | 2 | 0.190 |
Why?
|
| Premature Birth | 1 | 2024 | 132 | 0.190 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2022 | 29 | 0.190 |
Why?
|
| Program Evaluation | 2 | 2020 | 205 | 0.190 |
Why?
|
| Carboplatin | 3 | 2016 | 7 | 0.190 |
Why?
|
| Food Handling | 3 | 2003 | 6 | 0.190 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2022 | 19 | 0.190 |
Why?
|
| Leukemia | 1 | 2022 | 9 | 0.190 |
Why?
|
| Hallucinogens | 1 | 2022 | 23 | 0.190 |
Why?
|
| Diet, Macrobiotic | 1 | 2001 | 1 | 0.190 |
Why?
|
| Medicine, Chinese Traditional | 2 | 2011 | 3 | 0.180 |
Why?
|
| Drugs, Chinese Herbal | 2 | 2011 | 5 | 0.180 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 38 | 0.180 |
Why?
|
| Health Status | 4 | 2017 | 293 | 0.180 |
Why?
|
| Bevacizumab | 3 | 2016 | 8 | 0.180 |
Why?
|
| Pregnancy Complications | 1 | 2024 | 197 | 0.180 |
Why?
|
| Premenopause | 3 | 2017 | 24 | 0.180 |
Why?
|
| Patient Satisfaction | 2 | 2020 | 191 | 0.180 |
Why?
|
| Propensity Score | 2 | 2011 | 76 | 0.180 |
Why?
|
| Narration | 1 | 2021 | 8 | 0.180 |
Why?
|
| Tea | 2 | 1997 | 8 | 0.170 |
Why?
|
| Lipids | 5 | 1995 | 69 | 0.170 |
Why?
|
| Data Collection | 5 | 2019 | 238 | 0.170 |
Why?
|
| Carcinogenesis | 1 | 2020 | 9 | 0.170 |
Why?
|
| Cannabis | 1 | 2022 | 85 | 0.170 |
Why?
|
| Estrogen Receptor alpha | 3 | 2015 | 25 | 0.170 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2012 | 8 | 0.170 |
Why?
|
| Genetic Counseling | 1 | 2020 | 27 | 0.170 |
Why?
|
| Exome | 2 | 2022 | 21 | 0.170 |
Why?
|
| Diet, Fat-Restricted | 2 | 2002 | 36 | 0.170 |
Why?
|
| Gynecology | 1 | 2020 | 22 | 0.170 |
Why?
|
| DNA | 2 | 2022 | 23 | 0.170 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 16 | 0.170 |
Why?
|
| Income | 3 | 2016 | 86 | 0.160 |
Why?
|
| Research Personnel | 2 | 2017 | 28 | 0.160 |
Why?
|
| Protective Factors | 2 | 2016 | 32 | 0.160 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2000 | 21 | 0.160 |
Why?
|
| Prostatic Neoplasms | 3 | 2015 | 263 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2012 | 120 | 0.160 |
Why?
|
| Factor Analysis, Statistical | 1 | 2019 | 36 | 0.160 |
Why?
|
| Plants, Medicinal | 1 | 1999 | 2 | 0.160 |
Why?
|
| Waist-Height Ratio | 1 | 2019 | 1 | 0.160 |
Why?
|
| Phytotherapy | 1 | 1999 | 12 | 0.160 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 202 | 0.160 |
Why?
|
| Adipose Tissue | 4 | 2014 | 65 | 0.160 |
Why?
|
| Caprylates | 1 | 2019 | 4 | 0.160 |
Why?
|
| Mental Health | 1 | 2021 | 169 | 0.160 |
Why?
|
| Referral and Consultation | 1 | 2020 | 157 | 0.150 |
Why?
|
| Telemedicine | 1 | 2022 | 181 | 0.150 |
Why?
|
| Melanoma | 2 | 2009 | 35 | 0.150 |
Why?
|
| Carcinoma | 2 | 1996 | 22 | 0.150 |
Why?
|
| Prevalence | 5 | 2017 | 840 | 0.150 |
Why?
|
| Conflict of Interest | 1 | 2018 | 7 | 0.150 |
Why?
|
| Disclosure | 1 | 2018 | 16 | 0.150 |
Why?
|
| Skin Neoplasms | 2 | 2009 | 58 | 0.140 |
Why?
|
| Hair | 2 | 2015 | 7 | 0.140 |
Why?
|
| Genomics | 2 | 2015 | 56 | 0.140 |
Why?
|
| Mass Screening | 2 | 2017 | 672 | 0.140 |
Why?
|
| Fast Foods | 2 | 2017 | 12 | 0.140 |
Why?
|
| Patients | 1 | 2018 | 29 | 0.140 |
Why?
|
| Coffee | 1 | 1997 | 5 | 0.140 |
Why?
|
| Beverages | 2 | 2014 | 18 | 0.140 |
Why?
|
| Computer Communication Networks | 1 | 1997 | 9 | 0.140 |
Why?
|
| Minnesota | 9 | 2008 | 51 | 0.140 |
Why?
|
| Decision Making | 3 | 2017 | 171 | 0.140 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 35 | 0.140 |
Why?
|
| Mentors | 1 | 2017 | 8 | 0.140 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 55 | 0.140 |
Why?
|
| Epidemiology | 1 | 1997 | 6 | 0.130 |
Why?
|
| Epidemiologic Research Design | 1 | 2017 | 18 | 0.130 |
Why?
|
| Dietary Proteins | 7 | 2005 | 19 | 0.130 |
Why?
|
| Uterine Neoplasms | 2 | 1997 | 13 | 0.130 |
Why?
|
| Analysis of Variance | 4 | 2012 | 139 | 0.130 |
Why?
|
| Health Education | 1 | 1997 | 82 | 0.130 |
Why?
|
| Erythrocyte Membrane | 2 | 2000 | 4 | 0.130 |
Why?
|
| Lymphatic Metastasis | 3 | 2012 | 30 | 0.130 |
Why?
|
| Bone Diseases | 1 | 2016 | 3 | 0.130 |
Why?
|
| Bone Remodeling | 1 | 2016 | 5 | 0.130 |
Why?
|
| Child, Preschool | 4 | 2024 | 1380 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 381 | 0.130 |
Why?
|
| Patient Selection | 1 | 1997 | 176 | 0.130 |
Why?
|
| Renin-Angiotensin System | 1 | 2016 | 16 | 0.130 |
Why?
|
| Metabolic Equivalent | 1 | 2016 | 8 | 0.130 |
Why?
|
| Vehicle Emissions | 1 | 2016 | 23 | 0.130 |
Why?
|
| Ontario | 3 | 2022 | 19 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 1 | 1997 | 69 | 0.130 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 437 | 0.130 |
Why?
|
| Thyroid Hormones | 1 | 2016 | 7 | 0.120 |
Why?
|
| Adenoma | 1 | 2017 | 95 | 0.120 |
Why?
|
| Occult Blood | 1 | 2017 | 155 | 0.120 |
Why?
|
| Ultrasonography | 3 | 2020 | 33 | 0.120 |
Why?
|
| Air Pollutants | 1 | 2016 | 54 | 0.120 |
Why?
|
| Thiocyanates | 1 | 2015 | 1 | 0.120 |
Why?
|
| Perchlorates | 1 | 2015 | 2 | 0.120 |
Why?
|
| Nitrates | 1 | 2015 | 9 | 0.120 |
Why?
|
| Ambulatory Care | 1 | 2017 | 225 | 0.120 |
Why?
|
| SEER Program | 1 | 2015 | 92 | 0.120 |
Why?
|
| Plants, Edible | 1 | 1995 | 6 | 0.120 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 26 | 0.120 |
Why?
|
| Energy Metabolism | 4 | 2006 | 48 | 0.120 |
Why?
|
| Telomere | 1 | 2015 | 18 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 32 | 0.120 |
Why?
|
| Hypercholesterolemia | 1 | 1995 | 25 | 0.120 |
Why?
|
| Hyperlipidemias | 1 | 1995 | 44 | 0.120 |
Why?
|
| Blood Specimen Collection | 1 | 2015 | 7 | 0.120 |
Why?
|
| Neoplasm Grading | 4 | 2016 | 49 | 0.120 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2014 | 5 | 0.120 |
Why?
|
| Animals | 10 | 2009 | 280 | 0.120 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 16 | 0.110 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2024 | 31 | 0.110 |
Why?
|
| Choice Behavior | 2 | 2012 | 45 | 0.110 |
Why?
|
| Food Supply | 2 | 2014 | 41 | 0.110 |
Why?
|
| Body Height | 5 | 2016 | 60 | 0.110 |
Why?
|
| Infant | 2 | 2016 | 1161 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2013 | 123 | 0.110 |
Why?
|
| Confidence Intervals | 6 | 2021 | 231 | 0.110 |
Why?
|
| Parabens | 1 | 2014 | 4 | 0.110 |
Why?
|
| Snacks | 1 | 2014 | 3 | 0.110 |
Why?
|
| Nutritive Sweeteners | 1 | 2014 | 2 | 0.110 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2014 | 7 | 0.110 |
Why?
|
| Eating | 5 | 2002 | 34 | 0.110 |
Why?
|
| Social Environment | 1 | 2014 | 85 | 0.110 |
Why?
|
| Benzhydryl Compounds | 1 | 2014 | 26 | 0.110 |
Why?
|
| Models, Theoretical | 1 | 2014 | 67 | 0.110 |
Why?
|
| Focus Groups | 1 | 1994 | 143 | 0.110 |
Why?
|
| Blood Glucose | 2 | 2014 | 314 | 0.110 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2014 | 24 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2019 | 203 | 0.100 |
Why?
|
| Cholesterol, Dietary | 7 | 2001 | 8 | 0.100 |
Why?
|
| Plant Extracts | 1 | 2013 | 14 | 0.100 |
Why?
|
| Body Weights and Measures | 2 | 2017 | 13 | 0.100 |
Why?
|
| Cause of Death | 4 | 2021 | 176 | 0.100 |
Why?
|
| Mutation | 4 | 2020 | 132 | 0.100 |
Why?
|
| ErbB Receptors | 1 | 2012 | 5 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 7 | 0.100 |
Why?
|
| Carcinoma, Lobular | 1 | 2012 | 10 | 0.100 |
Why?
|
| Induction Chemotherapy | 1 | 2012 | 2 | 0.100 |
Why?
|
| Managed Care Programs | 1 | 2014 | 300 | 0.100 |
Why?
|
| Translational Medical Research | 1 | 2012 | 33 | 0.100 |
Why?
|
| Treatment Refusal | 1 | 2012 | 30 | 0.100 |
Why?
|
| Neoplasms, Second Primary | 1 | 2012 | 31 | 0.100 |
Why?
|
| Demography | 2 | 2010 | 93 | 0.100 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2013 | 68 | 0.100 |
Why?
|
| Folic Acid Deficiency | 2 | 2002 | 3 | 0.090 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2012 | 10 | 0.090 |
Why?
|
| Sex Distribution | 1 | 2012 | 180 | 0.090 |
Why?
|
| Selection Bias | 1 | 1991 | 16 | 0.090 |
Why?
|
| Physicians | 1 | 2013 | 117 | 0.090 |
Why?
|
| 4-Butyrolactone | 2 | 2013 | 2 | 0.090 |
Why?
|
| Diet, Reducing | 1 | 1991 | 22 | 0.090 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 31 | 0.090 |
Why?
|
| Societies | 1 | 2011 | 2 | 0.090 |
Why?
|
| Soybeans | 2 | 2001 | 4 | 0.090 |
Why?
|
| Transcriptome | 2 | 2025 | 25 | 0.090 |
Why?
|
| Primary Health Care | 1 | 2017 | 726 | 0.090 |
Why?
|
| Patient Participation | 1 | 2012 | 119 | 0.090 |
Why?
|
| Health Planning Guidelines | 1 | 2011 | 8 | 0.090 |
Why?
|
| Statistics as Topic | 3 | 2001 | 56 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 17 | 0.090 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 53 | 0.090 |
Why?
|
| Outpatients | 1 | 2012 | 101 | 0.090 |
Why?
|
| Commerce | 1 | 2011 | 36 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 197 | 0.090 |
Why?
|
| Diet Records | 4 | 2017 | 37 | 0.090 |
Why?
|
| Single-Parent Family | 1 | 2010 | 1 | 0.090 |
Why?
|
| Fathers | 1 | 2010 | 9 | 0.090 |
Why?
|
| Milk | 5 | 2009 | 8 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2025 | 99 | 0.080 |
Why?
|
| Infant, Newborn | 2 | 2024 | 805 | 0.080 |
Why?
|
| Insurance Coverage | 2 | 2022 | 104 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2010 | 44 | 0.080 |
Why?
|
| DDT | 1 | 2010 | 3 | 0.080 |
Why?
|
| Dichlorodiphenyl Dichloroethylene | 1 | 2010 | 4 | 0.080 |
Why?
|
| Asthma | 1 | 2013 | 400 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 367 | 0.080 |
Why?
|
| Guideline Adherence | 2 | 2024 | 149 | 0.080 |
Why?
|
| Anthropometry | 6 | 2001 | 60 | 0.080 |
Why?
|
| Adaptation, Psychological | 1 | 2010 | 78 | 0.080 |
Why?
|
| Weight Loss | 1 | 1991 | 294 | 0.080 |
Why?
|
| Selection, Genetic | 1 | 2009 | 2 | 0.080 |
Why?
|
| beta Carotene | 1 | 2008 | 17 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 102 | 0.070 |
Why?
|
| Myocardial Ischemia | 2 | 1999 | 23 | 0.070 |
Why?
|
| Research | 2 | 2019 | 61 | 0.070 |
Why?
|
| Nuts | 2 | 2001 | 4 | 0.070 |
Why?
|
| Geography | 1 | 2008 | 39 | 0.070 |
Why?
|
| Anthracyclines | 2 | 2022 | 14 | 0.070 |
Why?
|
| Blood Coagulation Factors | 1 | 1988 | 8 | 0.070 |
Why?
|
| Genotype | 2 | 2021 | 223 | 0.070 |
Why?
|
| Evaluation Studies as Topic | 3 | 2001 | 28 | 0.070 |
Why?
|
| Risk Reduction Behavior | 2 | 2009 | 104 | 0.070 |
Why?
|
| Bone and Bones | 2 | 2020 | 10 | 0.070 |
Why?
|
| Parity | 5 | 2000 | 57 | 0.070 |
Why?
|
| Caffeine | 2 | 2000 | 18 | 0.070 |
Why?
|
| Progesterone | 2 | 2006 | 5 | 0.070 |
Why?
|
| Quality Improvement | 2 | 2020 | 188 | 0.070 |
Why?
|
| Physical Fitness | 1 | 2007 | 70 | 0.070 |
Why?
|
| New York | 3 | 2017 | 17 | 0.070 |
Why?
|
| Isoflavones | 1 | 2007 | 14 | 0.070 |
Why?
|
| Eggs | 4 | 2009 | 8 | 0.070 |
Why?
|
| Bias | 4 | 1998 | 96 | 0.070 |
Why?
|
| Indians, North American | 2 | 1999 | 48 | 0.070 |
Why?
|
| Expert Testimony | 1 | 2006 | 5 | 0.060 |
Why?
|
| Estrogens | 2 | 2006 | 60 | 0.060 |
Why?
|
| Phenotype | 2 | 2022 | 149 | 0.060 |
Why?
|
| Waist Circumference | 2 | 2016 | 33 | 0.060 |
Why?
|
| Water Supply | 2 | 2013 | 8 | 0.060 |
Why?
|
| Hospitalization | 2 | 2025 | 804 | 0.060 |
Why?
|
| Cerebellar Neoplasms | 1 | 2005 | 2 | 0.060 |
Why?
|
| Medulloblastoma | 1 | 2005 | 3 | 0.060 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 1 | 2025 | 1 | 0.060 |
Why?
|
| Family Health | 3 | 1996 | 45 | 0.060 |
Why?
|
| DNA Helicases | 1 | 2025 | 3 | 0.060 |
Why?
|
| Chronic Disease | 3 | 2012 | 397 | 0.060 |
Why?
|
| Loss of Function Mutation | 1 | 2025 | 3 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2011 | 312 | 0.060 |
Why?
|
| Europe | 2 | 1995 | 46 | 0.060 |
Why?
|
| Guidelines as Topic | 2 | 2004 | 41 | 0.060 |
Why?
|
| Cardiomyopathies | 1 | 2025 | 9 | 0.060 |
Why?
|
| Patient Care Planning | 1 | 2024 | 45 | 0.060 |
Why?
|
| Cardiovascular Agents | 1 | 2024 | 22 | 0.060 |
Why?
|
| Pedigree | 4 | 2015 | 63 | 0.060 |
Why?
|
| Seroepidemiologic Studies | 1 | 2024 | 19 | 0.060 |
Why?
|
| Data Accuracy | 1 | 2024 | 24 | 0.060 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2024 | 7 | 0.060 |
Why?
|
| Cities | 2 | 2019 | 30 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2024 | 16 | 0.050 |
Why?
|
| Hawaii | 1 | 2024 | 58 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 2 | 2014 | 22 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 27 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2024 | 43 | 0.050 |
Why?
|
| Congresses as Topic | 2 | 2015 | 13 | 0.050 |
Why?
|
| Sample Size | 3 | 2003 | 26 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2014 | 72 | 0.050 |
Why?
|
| Health Surveys | 2 | 2002 | 245 | 0.050 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2024 | 54 | 0.050 |
Why?
|
| Cognitive Dysfunction | 1 | 2024 | 53 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2014 | 21 | 0.050 |
Why?
|
| Death | 1 | 2023 | 10 | 0.050 |
Why?
|
| Cystatin C | 1 | 2023 | 14 | 0.050 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2023 | 26 | 0.050 |
Why?
|
| Albumins | 1 | 2023 | 5 | 0.050 |
Why?
|
| Micronutrients | 2 | 2005 | 9 | 0.050 |
Why?
|
| Confounding Factors (Epidemiology) | 4 | 2007 | 84 | 0.050 |
Why?
|
| Abdomen | 2 | 2019 | 20 | 0.050 |
Why?
|
| Creatinine | 2 | 2017 | 66 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 24 | 0.050 |
Why?
|
| Whole Exome Sequencing | 1 | 2022 | 8 | 0.050 |
Why?
|
| Endopeptidase K | 1 | 2022 | 1 | 0.050 |
Why?
|
| Paraffin Embedding | 1 | 2022 | 5 | 0.050 |
Why?
|
| Tissue Fixation | 1 | 2022 | 3 | 0.050 |
Why?
|
| Life Change Events | 1 | 2022 | 31 | 0.050 |
Why?
|
| Formaldehyde | 1 | 2022 | 5 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2024 | 165 | 0.050 |
Why?
|
| Radiography | 1 | 2022 | 36 | 0.050 |
Why?
|
| Cultural Diversity | 1 | 2002 | 17 | 0.050 |
Why?
|
| Cluster Analysis | 4 | 1999 | 86 | 0.050 |
Why?
|
| Ventricular Function, Left | 1 | 2022 | 53 | 0.050 |
Why?
|
| Tumor Burden | 2 | 2012 | 19 | 0.050 |
Why?
|
| Outcome Assessment (Health Care) | 2 | 2000 | 215 | 0.050 |
Why?
|
| Herbal Medicine | 2 | 2011 | 2 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2021 | 33 | 0.050 |
Why?
|
| Cooking | 2 | 1998 | 17 | 0.050 |
Why?
|
| China | 4 | 2004 | 132 | 0.050 |
Why?
|
| Introns | 1 | 2021 | 9 | 0.050 |
Why?
|
| Hematinics | 1 | 2001 | 3 | 0.050 |
Why?
|
| Women | 2 | 1999 | 12 | 0.040 |
Why?
|
| Urban Population | 1 | 2002 | 109 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2022 | 104 | 0.040 |
Why?
|
| Ovary | 1 | 2020 | 5 | 0.040 |
Why?
|
| BRCA2 Protein | 1 | 2020 | 5 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2020 | 6 | 0.040 |
Why?
|
| Heterozygote | 1 | 2020 | 26 | 0.040 |
Why?
|
| Genetic Pleiotropy | 1 | 2020 | 9 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2001 | 105 | 0.040 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2000 | 42 | 0.040 |
Why?
|
| Regional Medical Programs | 1 | 2020 | 2 | 0.040 |
Why?
|
| Diseases in Twins | 1 | 2000 | 15 | 0.040 |
Why?
|
| Seafood | 2 | 2000 | 8 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 287 | 0.040 |
Why?
|
| Watchful Waiting | 1 | 2020 | 22 | 0.040 |
Why?
|
| Hip Fractures | 1 | 2000 | 71 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 3 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 2019 | 4 | 0.040 |
Why?
|
| Thorax | 1 | 2019 | 5 | 0.040 |
Why?
|
| Spine | 1 | 2019 | 8 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 8 | 0.040 |
Why?
|
| Head | 1 | 2019 | 6 | 0.040 |
Why?
|
| Likelihood Functions | 2 | 1999 | 45 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 2 | 0.040 |
Why?
|
| Radiation, Ionizing | 1 | 2019 | 3 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2019 | 6 | 0.040 |
Why?
|
| Waist-Hip Ratio | 1 | 2019 | 23 | 0.040 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 1996 | 26 | 0.040 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2020 | 42 | 0.040 |
Why?
|
| Causality | 1 | 1999 | 34 | 0.040 |
Why?
|
| Flavonoids | 1 | 1999 | 7 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 28 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2019 | 29 | 0.040 |
Why?
|
| Lactose | 1 | 1999 | 1 | 0.040 |
Why?
|
| Gestational Age | 1 | 2019 | 112 | 0.040 |
Why?
|
| Heterocyclic Compounds | 1 | 1998 | 1 | 0.040 |
Why?
|
| Vaccination | 1 | 2024 | 688 | 0.040 |
Why?
|
| Amines | 1 | 1998 | 5 | 0.040 |
Why?
|
| Asian Continental Ancestry Group | 1 | 1999 | 87 | 0.040 |
Why?
|
| Reproductive History | 2 | 1996 | 17 | 0.040 |
Why?
|
| Random Allocation | 2 | 1996 | 33 | 0.040 |
Why?
|
| Clinical Trials as Topic | 3 | 2012 | 120 | 0.040 |
Why?
|
| Medicaid | 1 | 2020 | 189 | 0.040 |
Why?
|
| Fishes | 2 | 2009 | 10 | 0.040 |
Why?
|
| Diabetes Mellitus | 2 | 2000 | 452 | 0.040 |
Why?
|
| Nuclear Family | 1 | 1998 | 7 | 0.040 |
Why?
|
| Dietary Fats, Unsaturated | 3 | 2007 | 4 | 0.040 |
Why?
|
| Disease Progression | 1 | 2019 | 259 | 0.040 |
Why?
|
| Prenatal Care | 1 | 2019 | 127 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 304 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2018 | 76 | 0.030 |
Why?
|
| Chlorine | 1 | 1997 | 1 | 0.030 |
Why?
|
| Food, Organic | 2 | 2011 | 4 | 0.030 |
Why?
|
| Rectal Neoplasms | 1 | 1998 | 75 | 0.030 |
Why?
|
| Intestinal Polyps | 1 | 2017 | 7 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2017 | 7 | 0.030 |
Why?
|
| Models, Genetic | 3 | 2006 | 23 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 10 | 0.030 |
Why?
|
| Diphosphonates | 1 | 2017 | 63 | 0.030 |
Why?
|
| Agriculture | 1 | 1996 | 7 | 0.030 |
Why?
|
| Fish Oils | 1 | 2016 | 2 | 0.030 |
Why?
|
| Therapeutic Touch | 1 | 2016 | 2 | 0.030 |
Why?
|
| Melatonin | 1 | 2016 | 4 | 0.030 |
Why?
|
| Plant Preparations | 1 | 2016 | 5 | 0.030 |
Why?
|
| Glucosamine | 1 | 2016 | 3 | 0.030 |
Why?
|
| Mind-Body Therapies | 1 | 2016 | 8 | 0.030 |
Why?
|
| Smoking Cessation | 2 | 2011 | 154 | 0.030 |
Why?
|
| Massage | 1 | 2016 | 16 | 0.030 |
Why?
|
| Meditation | 1 | 2016 | 17 | 0.030 |
Why?
|
| Yoga | 1 | 2016 | 25 | 0.030 |
Why?
|
| Attitude to Health | 1 | 1997 | 147 | 0.030 |
Why?
|
| Fatty Acids | 2 | 2007 | 8 | 0.030 |
Why?
|
| Food, Fortified | 1 | 1996 | 5 | 0.030 |
Why?
|
| Multigene Family | 1 | 2016 | 6 | 0.030 |
Why?
|
| Goals | 1 | 2016 | 27 | 0.030 |
Why?
|
| Heart Valve Diseases | 1 | 2016 | 17 | 0.030 |
Why?
|
| Acupuncture Therapy | 1 | 2016 | 32 | 0.030 |
Why?
|
| Ovulation | 1 | 1996 | 5 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2016 | 71 | 0.030 |
Why?
|
| Docosahexaenoic Acids | 1 | 1995 | 7 | 0.030 |
Why?
|
| Eicosapentaenoic Acid | 1 | 1995 | 9 | 0.030 |
Why?
|
| Symporters | 1 | 2015 | 1 | 0.030 |
Why?
|
| Iodine | 1 | 2015 | 3 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 1997 | 173 | 0.030 |
Why?
|
| Antithyroid Agents | 1 | 2015 | 3 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 8 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2015 | 24 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 24 | 0.030 |
Why?
|
| Neural Tube Defects | 1 | 1995 | 8 | 0.030 |
Why?
|
| Automation | 1 | 2015 | 25 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1997 | 131 | 0.030 |
Why?
|
| Quality Control | 1 | 2015 | 41 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 2 | 2012 | 81 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2015 | 19 | 0.030 |
Why?
|
| Wine | 1 | 1995 | 18 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 112 | 0.030 |
Why?
|
| Workplace | 1 | 1995 | 29 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2015 | 66 | 0.030 |
Why?
|
| Phylogeny | 1 | 2015 | 15 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 18 | 0.030 |
Why?
|
| Haplotypes | 1 | 2015 | 34 | 0.030 |
Why?
|
| Life Expectancy | 1 | 1995 | 34 | 0.030 |
Why?
|
| Plant Oils | 2 | 2007 | 4 | 0.030 |
Why?
|
| Child Development | 1 | 2015 | 53 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2014 | 47 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2015 | 50 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 89 | 0.030 |
Why?
|
| Middle East | 1 | 1994 | 2 | 0.030 |
Why?
|
| Asia, Southeastern | 1 | 1994 | 4 | 0.030 |
Why?
|
| Teaching Materials | 1 | 1994 | 4 | 0.030 |
Why?
|
| Food Preservatives | 1 | 2014 | 1 | 0.030 |
Why?
|
| Food Packaging | 1 | 2014 | 2 | 0.030 |
Why?
|
| Fee-for-Service Plans | 1 | 2014 | 21 | 0.030 |
Why?
|
| Dietary Sucrose | 1 | 2014 | 13 | 0.030 |
Why?
|
| Restaurants | 1 | 2014 | 17 | 0.030 |
Why?
|
| Child Behavior | 1 | 2014 | 22 | 0.030 |
Why?
|
| Utah | 1 | 2014 | 32 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 342 | 0.030 |
Why?
|
| Sucrose | 1 | 1994 | 6 | 0.030 |
Why?
|
| Forecasting | 1 | 2014 | 68 | 0.030 |
Why?
|
| Respiratory Sounds | 1 | 2013 | 12 | 0.030 |
Why?
|
| Water Purification | 1 | 2013 | 1 | 0.030 |
Why?
|
| Cough | 1 | 2013 | 22 | 0.030 |
Why?
|
| Environmental Pollution | 1 | 2013 | 4 | 0.030 |
Why?
|
| Drinking Water | 1 | 2013 | 5 | 0.030 |
Why?
|
| Recurrence | 1 | 2014 | 165 | 0.030 |
Why?
|
| Internet | 1 | 2015 | 212 | 0.030 |
Why?
|
| Motivation | 1 | 1994 | 115 | 0.030 |
Why?
|
| Marital Status | 1 | 2013 | 20 | 0.030 |
Why?
|
| Infertility, Female | 1 | 1993 | 11 | 0.030 |
Why?
|
| Medicare | 1 | 2014 | 192 | 0.030 |
Why?
|
| Syndrome | 1 | 1993 | 28 | 0.030 |
Why?
|
| Michigan | 1 | 2012 | 28 | 0.020 |
Why?
|
| Japan | 1 | 1992 | 14 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2012 | 6 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 211 | 0.020 |
Why?
|
| Carotenoids | 1 | 2011 | 28 | 0.020 |
Why?
|
| Budgets | 1 | 2011 | 5 | 0.020 |
Why?
|
| Recreation | 1 | 2012 | 39 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 2011 | 15 | 0.020 |
Why?
|
| Warfarin | 1 | 2012 | 72 | 0.020 |
Why?
|
| Telephone | 1 | 1992 | 150 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 124 | 0.020 |
Why?
|
| Magnesium | 2 | 2001 | 6 | 0.020 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2010 | 19 | 0.020 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2010 | 23 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 6 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 10 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 2010 | 146 | 0.020 |
Why?
|
| South Africa | 1 | 1988 | 17 | 0.020 |
Why?
|
| Glutathione Transferase | 1 | 2008 | 13 | 0.020 |
Why?
|
| Poultry | 1 | 2007 | 2 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2007 | 20 | 0.020 |
Why?
|
| Vitamin B Complex | 1 | 2005 | 2 | 0.020 |
Why?
|
| Candy | 1 | 2005 | 2 | 0.020 |
Why?
|
| Maternal Welfare | 1 | 2005 | 12 | 0.020 |
Why?
|
| Ireland | 1 | 1985 | 3 | 0.010 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 1985 | 5 | 0.010 |
Why?
|
| Boston | 1 | 1985 | 28 | 0.010 |
Why?
|
| Sex Factors | 2 | 2000 | 603 | 0.010 |
Why?
|
| Genetic Linkage | 2 | 1995 | 7 | 0.010 |
Why?
|
| Calibration | 1 | 2004 | 7 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2004 | 71 | 0.010 |
Why?
|
| Weight Gain | 1 | 2005 | 156 | 0.010 |
Why?
|
| Nutritional Support | 1 | 2003 | 2 | 0.010 |
Why?
|
| Foodborne Diseases | 1 | 2003 | 5 | 0.010 |
Why?
|
| Seasons | 1 | 2004 | 113 | 0.010 |
Why?
|
| Acetaldehyde | 1 | 2002 | 1 | 0.010 |
Why?
|
| Maternal Age | 2 | 1993 | 74 | 0.010 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2002 | 8 | 0.010 |
Why?
|
| Probability | 1 | 2001 | 71 | 0.010 |
Why?
|
| Age Distribution | 1 | 2001 | 239 | 0.010 |
Why?
|
| Calcium | 1 | 2000 | 30 | 0.010 |
Why?
|
| Twins, Dizygotic | 1 | 2000 | 7 | 0.010 |
Why?
|
| Twins, Monozygotic | 1 | 2000 | 11 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 1999 | 1 | 0.010 |
Why?
|
| Cocarcinogenesis | 1 | 1999 | 2 | 0.010 |
Why?
|
| Penetrance | 1 | 1999 | 3 | 0.010 |
Why?
|
| Calorimetry, Indirect | 1 | 1999 | 2 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1999 | 36 | 0.010 |
Why?
|
| Genetics, Population | 1 | 1999 | 8 | 0.010 |
Why?
|
| Heart Rate | 1 | 1999 | 38 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1999 | 37 | 0.010 |
Why?
|
| Child Welfare | 1 | 1999 | 40 | 0.010 |
Why?
|
| Schools | 1 | 1999 | 88 | 0.010 |
Why?
|
| Nutritional Requirements | 1 | 1998 | 4 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1997 | 26 | 0.010 |
Why?
|
| Reproduction | 1 | 1997 | 12 | 0.010 |
Why?
|
| Observer Variation | 1 | 1996 | 36 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 1997 | 169 | 0.010 |
Why?
|
| Genetic Heterogeneity | 1 | 1996 | 3 | 0.010 |
Why?
|
| Pharyngeal Neoplasms | 1 | 1995 | 2 | 0.010 |
Why?
|
| Mouth Neoplasms | 1 | 1995 | 9 | 0.010 |
Why?
|
| Diet Therapy | 1 | 1995 | 9 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 1995 | 42 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1995 | 23 | 0.010 |
Why?
|
| Animal Population Groups | 1 | 1994 | 1 | 0.010 |
Why?
|
| Plants | 1 | 1994 | 2 | 0.010 |
Why?
|
| Fats | 1 | 1994 | 2 | 0.010 |
Why?
|
| Esophageal Neoplasms | 1 | 1995 | 115 | 0.010 |
Why?
|
| Reference Values | 1 | 1994 | 87 | 0.010 |
Why?
|
| DNA Damage | 1 | 1993 | 2 | 0.010 |
Why?
|
| Christianity | 1 | 1993 | 3 | 0.010 |
Why?
|
| Triglycerides | 1 | 1994 | 83 | 0.010 |
Why?
|
| Alcoholism | 1 | 1997 | 337 | 0.010 |
Why?
|
| Marriage | 1 | 1993 | 3 | 0.010 |
Why?
|
| Abortion, Spontaneous | 1 | 1993 | 49 | 0.010 |
Why?
|
| Family | 1 | 1992 | 106 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1991 | 4 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1991 | 5 | 0.010 |
Why?
|
| Rats | 1 | 1991 | 35 | 0.010 |
Why?
|
| Apolipoproteins A | 1 | 1988 | 1 | 0.000 |
Why?
|
| Apolipoproteins B | 1 | 1988 | 6 | 0.000 |
Why?
|
| Cholesterol, LDL | 1 | 1988 | 112 | 0.000 |
Why?
|